Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

5.20USD
20 Nov 2017
Change (% chg)

$-0.17 (-3.17%)
Prev Close
$5.37
Open
$5.41
Day's High
$5.65
Day's Low
$5.07
Volume
198,402
Avg. Vol
172,286
52-wk High
$15.01
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

Billionaire founder of Insys pleads not guilty to opioid bribe scheme

BOSTON The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients.

17 Nov 2017

UPDATE 2-Billionaire founder of Insys pleads not guilty to opioid bribe scheme

BOSTON, Nov 16 The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients.

17 Nov 2017

Billionaire founder of Insys to plead not guilty to opioid bribe scheme

BOSTON, Nov 16 The billionaire founder of Insys Therapeutics Inc was expected to appear in federal court in Boston on Thursday to plead not guilty to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug.

16 Nov 2017

Insys posts loss after founder charged in U.S. opioid bribe case

BOSTON Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company.

02 Nov 2017

UPDATE 2-Insys posts loss after founder charged in U.S. opioid bribe case

BOSTON, Nov 2 Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company.

02 Nov 2017

Insys posts bigger loss amid bribery probe of founder

Insys Therapeutics on Thursday posted a quarterly loss that was bigger than analysts' expectations, as it faced soft demand for its flagship opioid painkiller Subsys, which is at the center of a federal probe at the company.

02 Nov 2017

BRIEF-Insys Therapeutics reports Q3 loss per share of $2.30

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

02 Nov 2017

Insys Therapeutics posts net loss in third quarter

Nov 2 Insys Therapeutics on Thursday reported a net loss for the third quarter, compared to a year-ago profit, amid an investigation of the U.S. drugmaker's founder on charges of bribery.

02 Nov 2017

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc , has resigned as chairman of drugmaker Akorn Inc , just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

01 Nov 2017

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc, has resigned as chairman of drugmaker Akorn Inc, just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

01 Nov 2017

Earnings vs. Estimates